{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:14:10Z","timestamp":1792718050403,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth Analg Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Malignant hyperthermia (MH) syndrome is a rare pharmacogenetic disorder that can be highly life-threatening if diagnosis and treatment are delayed. The purpose of this study is to assess the knowledge and current practices of Italian anesthesiogists in managing malignant hyperthermia episodes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a national survey. Data were collected via an online questionnaire distributed by the Italian Society of Anaesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI). Responses were collected over 15\u00a0weeks between July 15 and October 15, 2024, using an online General Data Protection Regulation-compliant platform.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 395 anesthetists completed the survey. The majority are employed in public (35%) and university hospitals (26%), with an average of 20\u00a0years of professional experience. MH had been managed at least once by 31% of respondents, and 70% of them declared they always report adverse reactions.<\/jats:p>\n                    <jats:p>In over 90% of cases, preventive measures (removal of trigger drugs, ventilator wash-out, perioperative care) are identified, although only 49% reported having an internal protocol in place at their institution.<\/jats:p>\n                    <jats:p>In most centers (89%), non-anesthesiologists are responsible for the storage and supply of dantrolene and only 66% of respondents correctly identify sterile water as its appropriate solvent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our results highlight the need for broader standardization of MH management. Despite limitation in sample size and difference in geographical and hospital setting, the survey reveals a discrepancy between clinical practice and recommended strategies. Although the need for preventive measures as a mean to avoid episodes of MH is widely recognized, there continues to be too much ambiguity on what the exact protocol should be in these situations, leaving room to develop an unequivocal approach that allows the optimal treatment for episodes of MH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s44158-025-00293-4","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:31:10Z","timestamp":1763548270000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["National insights on malignant hyperthermia: a SIAARTI survey on clinical practices, preparedness, and future directions"],"prefix":"10.1186","volume":"5","author":[{"given":"Roberta","family":"Monzani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Alampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bignami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cortegiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Giarratano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Racca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Sbaraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"293_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0310-1","volume":"10","author":"H Rosenberg","year":"2015","unstructured":"Rosenberg H, Pollock N, Schiemann AH, Bulger T, Stowell KM (2015) Malignant hyperthermia: a review. Orphanet J Rare Dis 10:93","journal-title":"Orphanet J Rare Dis"},{"key":"293_CR2","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/8340209","volume":"2023","author":"Y Toyota","year":"2023","unstructured":"Toyota Y, Kondo T, Shorin D, Sumii A, Kido K, Watanabe T et al (2023) Rapid dantrolene administration with body temperature monitoring is associated with decreased mortality in Japanese malignant hyperthermia events. Biomed Res Int 2023:8340209","journal-title":"Biomed Res Int"},{"issue":"1","key":"293_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.anclin.2019.10.010","volume":"38","author":"H Ellinas","year":"2020","unstructured":"Ellinas H, Albrecht MA (2020) Malignant hyperthermia update. Anesthesiol Clin 38(1):165\u2013181","journal-title":"Anesthesiol Clin"},{"issue":"12","key":"293_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12123869","volume":"12","author":"L Frassanito","year":"2023","unstructured":"Frassanito L, Sbaraglia F, Piersanti A, Vassalli F, Lucente M, Filetici N et al (2023) Real evidence and misconceptions about Malignant Hyperthermia in children: a narrative review. J Clin Med 12(12):3869","journal-title":"J Clin Med"},{"issue":"3","key":"293_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/pst.1848","volume":"17","author":"F Miller","year":"2018","unstructured":"Miller F, Zohar S, Stallard N, Madan J, Posch M, Hee SW et al (2018) Approaches to sample size calculation for clinical trials in rare diseases. Pharm Stat 17(3):214\u2013230","journal-title":"Pharm Stat"},{"key":"293_CR6","unstructured":"Sbaraglia F, Racca F, Maiellare F, Longhitano Y, Zanza C, Caputo CT. Prevenzione, Gestione e Trattamento Dell\u2019ipertermia Maligna. 2020. Available online: www.siaarti.it (accessed on 10 April 2023). Italian"},{"key":"293_CR7","doi-asserted-by":"crossref","unstructured":"Ng Kwet Shing RH, Clayton LB, Smith SL, Watson MJ, McKenzie LM, Chalmers DP, et al. The novel rapid formulation of intravenous dantrolene (NPJ5008) versus standard dantrolene (Dantrium): A clinical part-randomised phase 1 study in healthy volunteers. .Eur J Anaesthesiol 2024 May 1;41(5):381\u2013390.","DOI":"10.1097\/EJA.0000000000001966"},{"issue":"5","key":"293_CR8","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1213\/ANE.0000000000004399","volume":"129","author":"MG Larach","year":"2019","unstructured":"Larach MG, Riazi S, Rosenberg H (2019) Dantrolene should be readily available wherever malignant hyperthermia triggering drugs are stocked. Anesth Analg 129(5):e175\u2013e176","journal-title":"Anesth Analg"},{"key":"293_CR9","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1213\/ane.0b013e3181ac1548","volume":"109","author":"JE Brady","year":"2009","unstructured":"Brady JE, Sun LS, Rosenberg H, Li G (2009) Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001\u20132005. Anesth Analg 109:1162\u20131166","journal-title":"Anesth Analg"},{"key":"293_CR10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1097\/EJA.0000000000000672","volume":"34","author":"M Schieren","year":"2017","unstructured":"Schieren M, Defosse J, B\u00f6hmer A, Wappler F, Gerbershagen MU (2017) Anaesthetic management of patients with myopathies. Eur J Anaesthesiol 34:641\u2013649","journal-title":"Eur J Anaesthesiol"},{"key":"293_CR11","doi-asserted-by":"publisher","DOI":"10.5812\/aapm-132088","volume":"13","author":"P Radkowski","year":"2023","unstructured":"Radkowski P, Suren L, Podhorodecka K, Harikumar S, Jamrozik N (2023) A review on the anesthetic management of patients with neuromuscular diseases. Anesthesiol Pain Med 13:e132088","journal-title":"Anesthesiol Pain Med"},{"issue":"1","key":"293_CR12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bja.2024.09.022","volume":"134","author":"KPE Glahn","year":"2025","unstructured":"Glahn KPE, Girard T, Hellblom A, Hopkins PM, Johannsen S, R\u00fcffert H et al (2025) Recognition and management of a malignant hyperthermia crisis: updated 2024 guideline from the European Malignant Hyperthermia Group. Br J Anaesth 134(1):221\u2013223","journal-title":"Br J Anaesth"},{"issue":"5","key":"293_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/anae.15317","volume":"76","author":"PM Hopkins","year":"2021","unstructured":"Hopkins PM, Girard T, Dalay S, Jenkins B, Thacker A, Patteril M et al (2021) Malignant hyperthermia 2020: guideline from the association of anaesthetists. Anaesthesia 76(5):655\u2013664","journal-title":"Anaesthesia"},{"key":"293_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.bja.2020.09.029","volume":"126","author":"H R\u00fcffert","year":"2021","unstructured":"R\u00fcffert H, Bastian B, Bendixen D, Girard T, Heiderich S, Hellblom A et al (2021) Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth 126:120\u2013130","journal-title":"Br J Anaesth"},{"key":"293_CR15","doi-asserted-by":"crossref","unstructured":"Schuster F, Johannsen S. [Malignant Hyperthermia and Pregnancy - Guidelines of the European Malignant Hyperthermia Group]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2021 May;56(5):367\u2013372. German.","DOI":"10.1055\/a-1260-8975"},{"key":"293_CR16","doi-asserted-by":"crossref","unstructured":"Ng Kwet Shing RH, Wright DJ, Pal S, Smith SL, Clayton LB, Bilmen JG. 2-Hydroxypropyl-\u03b2-cyclodextrin, solubiliser in a novel dantrolene formulation: Its binding affinities to clinical compounds that may be used during anaesthesia or management of malignant hyperthermia. Eur J Pharm Biopharm. 2025 Jun 5:114765","DOI":"10.1016\/j.ejpb.2025.114765"},{"issue":"2","key":"293_CR17","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.aorn.2013.06.012","volume":"99","author":"CL Cain","year":"2014","unstructured":"Cain CL, Riess ML, Gettrust L, Novalija J (2014) Malignant hyperthermia crisis: optimizing patient outcomes through simulation and interdisciplinary collaboration. AORN J 99(2):300\u2013311","journal-title":"AORN J"},{"key":"293_CR18","doi-asserted-by":"crossref","unstructured":"Rodrigues G, de Andrade PV, Dos Santos JM, do Amaral JLG, da Silva HCA.(2022) Impact of a digital manual for guidance on malignant hyperthermia: patient education. Orphanet J Rare Dis 17(1):265.","DOI":"10.1186\/s13023-022-02435-1"},{"issue":"9","key":"293_CR19","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1037\/apl0000120","volume":"101","author":"AM Hughes","year":"2016","unstructured":"Hughes AM, Gregory ME, Joseph DL, Sonesh SC, Marlow SL, Lacerenza CN et al (2016) Saving lives: a meta-analysis of team training in healthcare. J Appl Psychol 101(9):1266\u20131304","journal-title":"J Appl Psychol"},{"issue":"1","key":"293_CR20","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s12909-025-07062-5","volume":"25","author":"V Popov","year":"2025","unstructured":"Popov V (2025Apr 3) Rochlen LR From communication to action: using ordered network analysis to model team performance in clinical simulation. BMC Med Educ 25(1):479","journal-title":"BMC Med Educ"},{"issue":"2","key":"293_CR21","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1213\/ANE.0000000000004257","volume":"129","author":"RD Urman","year":"2019","unstructured":"Urman RD, Rajan N, Belani K, Gayer S, Joshi GP (2019) Malignant hyperthermia-susceptible adult patient and ambulatory surgery center: Society for Ambulatory Anesthesia and Ambulatory Surgical Care Committee of the American Society of Anesthesiologists position statement. Anesth Analg 129(2):347\u2013349","journal-title":"Anesth Analg"},{"issue":"9","key":"293_CR22","volume":"16","author":"W Harfaoui","year":"2024","unstructured":"Harfaoui W, Alilou M, El Adib AR, Zidouh S, Zentar A, Lekehal B et al (2024Sep 16) Patient Safety in Anesthesiology: Progress, Challenges, and Prospects. Cureus 16(9):e69540","journal-title":"Cureus"},{"issue":"1","key":"293_CR23","doi-asserted-by":"publisher","first-page":"2417399","DOI":"10.1080\/20523211.2024.2417399","volume":"17","author":"MAA Khan","year":"2024","unstructured":"Khan MAA, Sara T, Babar ZU (2024Oct 23) Pharmacovigilance: the evolution of drug safety monitoring. J Pharm Policy Pract 17(1):2417399","journal-title":"J Pharm Policy Pract"},{"issue":"1","key":"293_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s44158-025-00231-4","volume":"5","author":"M Greco","year":"2025","unstructured":"Greco M, Luca E, Chiumiento F, Behr AU, Bettelli G, Bignami E et al (2025) Perioperative assessment and management of frailty in elderly patients: a national survey of Italian anesthesiologists. J Anesth Analg Crit Care 5(1):11","journal-title":"J Anesth Analg Crit Care"}],"container-title":["Journal of Anesthesia, Analgesia and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-025-00293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44158-025-00293-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-025-00293-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:31:12Z","timestamp":1763548272000},"score":1,"resource":{"primary":{"URL":"https:\/\/janesthanalgcritcare.biomedcentral.com\/articles\/10.1186\/s44158-025-00293-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["293"],"URL":"https:\/\/doi.org\/10.1186\/s44158-025-00293-4","relation":{},"ISSN":["2731-3786"],"issn-type":[{"value":"2731-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}